- Home
- GRPN vs CTNM Comparison
GRPN vs CTNM Comparison
Compare GRPN & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GRPN | CTNM |
|---|---|---|
| Founded | 2008 | 2009 |
| Country | United States | United States |
| Employees | N/A | 41 |
| Industry | Advertising | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 576.7M | 507.0M |
| IPO Year | 2011 | 2024 |
Fundamental Metrics
Financial Performance| Metric | GRPN | CTNM |
|---|---|---|
| Price | $11.98 | $13.64 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $31.25 | $19.80 |
| AVG Volume (30 Days) | ★ 825.7K | 174.8K |
| Earning Date | 01-01-0001 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 14.69 | 0.46 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,843,877,000.00 | N/A |
| Revenue This Year | $4.17 | N/A |
| Revenue Next Year | $10.63 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.21 | $3.35 |
| 52 Week High | $41.26 | $16.33 |
Technical Indicators
Market Signals| Indicator | GRPN | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 36.85 | 42.36 |
| Support Level | $11.86 | $10.17 |
| Resistance Level | $13.80 | $16.17 |
| Average True Range (ATR) | 0.71 | 0.98 |
| MACD | 0.09 | -0.35 |
| Stochastic Oscillator | 15.21 | 11.18 |
Price Performance
Historical ComparisonAbout GRPN Groupon Inc.
Groupon Inc acts as the middleman between consumers and merchants, offering products and services at discounts via its online store. It offers consumers daily deals from local merchants. The company's operations are organized into two segments: North America and International. The company generates the majority of its revenue from North America. The company generates revenue from transactions during which the company generates commissions by selling goods or services on behalf of third-party merchants. Revenue also includes commissions the company earn when customers make purchases with retailers using digital coupons accessed through its digital properties.
About CTNM Contineum Therapeutics Inc.
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.